• Rezubio initiates Phase 1 trial of RZ-520 inhaled therapy in development for the treatment of respiratory diseases

  Chinese biotech Rezubio has announced the initiation of a Phase 1 PK/PD study of RZ-520, which Rezubio describes as “a novel inhaled therapeutic drug candidate for the treatment of chronic respiratory diseases.” According to Rezubio,… [Read more . . .]

• FDA grants Fast Track designation to Liquidia’s Yutrepia treprostinil DPI for the treatment of Raynaud’s phenomenon in systemic sclerosis

  According to Liquidia, the FDA has granted Fast Track designation to the company’s Yutrepia inhaled dry powder treprostinil for the treatment of Raynaud’s phenomenon associated with systemic sclerosis (SSc-RP.). Yutrepia is currently approved in the… [Read more . . .]

• Chiesi announces European regulatory submissions for LGWP formulations of BDP/FF/GB and BDP/FF MDIs

  Chiesi has announced the acceptance of regulatory submissions for two LGWP versions of its metered dose inhalers that have been reformulated with Orbia‘s HFA 152a propellant. In the UK, the MHRA recently approved Chiesi’s HFA 152a Clenil Modulite beclometasone MDI for… [Read more . . .]

• Aptar announces that Nanopharm will provide development services for Aceso’s ACT-101 antisense oligonucleotide for CF

  Aptar Pharma has announced a deal with French biotech Aceso Therapeutics related to development of Aceso’s ACT-101 antisense oligonucleotide for the treatment of cystic fibrosis. According to Aptar, its subsidiary Nanopharm will provide development services… [Read more . . .]

• Copley Scientific launches Inhalytix+ v2.0 and Critical Flow Controller TPK 200iX

  Inhaler testing specialist Copley Scientific has announced the launch of its new Inhalytix+ v2.0 and Critical Flow Controller TPK 200iX. The company launched  Version 1 of Inhalytix+, a subscription-based cascade impactor software package, in August 2025. The TPK… [Read more . . .]

• Chinese NMPA approves Milestone and Everest’s Cardamyst etripamil nasal spray for the treatment of PSVT

• Nemera launches DuoSpray bidose nasal delivery device for systemic drugs

• FDA accepts United Therapeutics’ sNDA to extend use of Tyvaso treprostinil inhalation solution for the treatment of IPF

• Lannett launches generic version of Advair Diskus in the US

• ENA Respiratory awarded almost AU$3 million funding to support Phase 1b trial of INNA-051 intranasal dry powder TLR2/6 agonist in patients with asthma

More news . . .